Osteogenic Growth Peptide (10-14) is a truncated pentapeptide fragment of the active osteogenic growth peptide (OGP) and is a Src kinase (Src) inhibitor [1-2]. Osteogenic Growth Peptide (10-14) binds to the OGP receptor and activates the Gi protein-MAP kinase signaling pathway [3]. Osteogenic Growth Peptide (10-14) is a potent mitogen and bone formation and hematopoietic stimulator, which can be used to treat osteoporosis and periodontitis [4].
In vitro, Osteogenic Growth Peptide (10-14) (0.01, 0.1, 1, 10, and 100nM; 1, 5, and 7 days) treated human periodontal ligament stem cells (hPDLSCs), and at low concentrations (0.01, 0.1, and 1nM), it significantly enhanced cell proliferation and osteogenic differentiation potential, while at concentrations of 10 and 100nM, there was no related response [5]. Osteogenic Growth Peptide (10-14) (0.1nM; 7-21 days) treatment significantly promoted osteogenic differentiation of bone marrow mesenchymal stem cells (MSCs), inhibited adipocyte formation, increased alkaline phosphatase (ALP) activity and mineralization nodules formation, and stimulated osteoblast-specific mRNA expression of nuclear factor 1 (cbfa1), and inhibited adipocyte-specific mRNA expression of peroxisome proliferator-activated receptor gamma-2 (PPARγ2) [6].
In vivo, Osteogenic Growth Peptide (10-14) (1nmol/kg/day; 35 days; s.c.) could significantly alleviate bone loss in female mice that underwent ovarian removal (OVX) 30 days before the start of anabolic therapy, and increase the number of osteogenic cells in the mice [7].
References:
[1] Chen YC, et al. Bioactive pseudopeptidic analogues and cyclostereoisomers of osteogenic growth peptide C-terminal pentapeptide, OGP(10-14). J Med Chem. 2002;45(8):1624-1632.
[2] Battolla B, et al. The small peptide OGP(10-14) reduces proliferation and induces differentiation of TPO-primed M07-e cells through RhoA/TGFbeta1/SFK pathway. Med Sci Monit. 2011;17(1):SC1-SC5.
[3] Chen Z, et al. Regulation of endochondral ossification by osteogenic growth peptide C-terminal pentapeptide [OGP(10-14)]. Protein Pept Lett. 2009;16(9):1074-1080.
[4] Fazzi R, et al. Bone and bone-marrow interactions: haematological activity of osteoblastic growth peptide (OGP)-derived carboxy-terminal pentapeptide. Mobilizing properties on white blood cells and peripheral blood stem cells in mice. Leuk Res. 2002;26(1)
[5] Purbantoro S D, Osathanon T, Nantavisai S, et al. Osteogenic growth peptide enhances osteogenic differentiation of human periodontal ligament stem cells[J]. Heliyon, 2022, 8(7).
[6] Chen ZX, Chang M, Peng YL, et al. Osteogenic growth peptide C-terminal pentapeptide [OGP(10-14)] acts on rat bone marrow mesenchymal stem cells to promote differentiation to osteoblasts and to inhibit differentiation to adipocytes. Regul Pept. 2007;142(1-2):16-23.
[7] Bab I, Chorev M. Osteogenic growth peptide: from concept to drug design[J]. Peptide Science: Original Research on Biomolecules, 2002, 66(1): 33-48.
Osteogenic Growth Peptide (10-14)是具有活性的成骨生长肽（OGP）的C端截短的五肽片段，是一种Src kinase（Src）抑制剂 [1-2]。Osteogenic Growth Peptide (10-14)与OGP受体结合，并激活细胞内的Gi蛋白-MAP激酶信号通路 [3]。成骨生长肽（10-14）是一种强效的有丝分裂原和骨生成及造血刺激剂，可用于治疗骨质疏松症和牙周炎 [4]。
在体外，Osteogenic Growth Peptide (10-14)（0.01, 0.1, 1, 10, and 100nM; 1, 5, and 7 days）处理人牙周膜干细胞（hPDLSCs），在低浓度下（0.01、0.1和1nM）显著增强了细胞增殖和成骨分化潜力，而10和100nM浓度下无相关反应 [5]。Osteogenic Growth Peptide (10-14)（0.1nM; 7-21 days）处理显著促进了骨髓间质干细胞（MSCs）的成骨分化，抑制脂肪细胞的形成，增加了碱性磷酸酶（ALP）活性和矿化结节的形成，并刺激核结合因子1（cbfa1）的成骨细胞特异性mRNA表达，并抑制了过氧化物酶增殖物激活受体γ-2（PPARγ2）的脂肪细胞特异性mRNA表达 [6]。
在体内，Osteogenic Growth Peptide (10-14)（1nmol/kg/day; 35 days; s.c.）能够显著缓解在合成代谢治疗开始前30天进行卵巢切除（OVX）的雌性小鼠的骨质流失，增加了小鼠成骨的细胞数量 [7]。